Search
Menu
Alluxa - Optical Coatings LB 8/23

Bayer HealthCare

Facebook X LinkedIn Email
Bayer HealthCare of Berlin has entered into a strategic agreement to transfer its hematological oncology portfolio to Genzyme Corp. of Cambridge, Mass. This includes granting the American company exclusive worldwide licenses for several of the products in the portfolio. In return, the German company will receive milestone payments and royalties, which could add up to as much as $650 million.Read full article

Related content from Photonics Media



    Articles


    Products


    Photonics Handbook Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories


    Companies
    Published: July 2009
    Bayer HealthcareBiophotonicshematological oncologyNews & Features

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.